Page 11234..1020..»

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

Posted: May 18, 2024 at 2:42 am

MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders.

Originally posted here:
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

Posted in Global News Feed | Comments Off on BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Posted: May 18, 2024 at 2:42 am

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.

More here:
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Posted in Global News Feed | Comments Off on Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Better Choice Company Announces First Quarter 2024 Results

Posted: May 18, 2024 at 2:42 am

EPS Growth of 28% Year Over Year to $(3.60)Adjusted EBITDA1 Growth of 27% Year Over Year to $(1.4) MillionAdjusted EBITDA Margin1 of (18)%, a 299 Basis Point Expansion Year Over Year

See the rest here:
Better Choice Company Announces First Quarter 2024 Results

Posted in Global News Feed | Comments Off on Better Choice Company Announces First Quarter 2024 Results

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Posted: May 18, 2024 at 2:42 am

Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.

More:
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Posted in Global News Feed | Comments Off on More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology

Posted: May 18, 2024 at 2:42 am

Phase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia congenita

Continue reading here:
Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology

Posted in Global News Feed | Comments Off on Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology

Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin…

Posted: May 18, 2024 at 2:42 am

-- In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic

Go here to read the rest:
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin...

Posted in Global News Feed | Comments Off on Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin…

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

Posted: May 18, 2024 at 2:42 am

TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations. With a distinguished background in the pharmaceutical industry, including significant tenure and pivotal roles at Teva Pharmaceuticals, Dr. Petter’s addition signals NurExone’s readiness for industry partnerships and licensing agreements.

Visit link:
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

Posted in Global News Feed | Comments Off on NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

Posted: May 18, 2024 at 2:42 am

FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a virtual fireside chat at UBS Obesity Therapeutics Day on Thursday, May 23, 2024 at 1:00 p.m. ET.

Read more from the original source:
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

Posted in Global News Feed | Comments Off on Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

DBV Technologies Announces Plan to Implement ADS Ratio Change

Posted: May 18, 2024 at 2:42 am

Châtillon, France, May 17, 2024

Originally posted here:
DBV Technologies Announces Plan to Implement ADS Ratio Change

Posted in Global News Feed | Comments Off on DBV Technologies Announces Plan to Implement ADS Ratio Change

Oculis updates share capital for its existing at-the-market offering program

Posted: May 18, 2024 at 2:42 am

ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 1,000,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 46,443,700, of which 41.7 million shares are outstanding.

Read the rest here:
Oculis updates share capital for its existing at-the-market offering program

Posted in Global News Feed | Comments Off on Oculis updates share capital for its existing at-the-market offering program

Page 11234..1020..»